Spinogenix announced open enrollment for the phase 2 trial of SPG302, the first synaptic regenerative approach to treat schizophrenia with the potential to improve outcomes across all symptom domains.
News
Yesterday marked a somber National Doctors’ Day…
Here are highlights from this week in Psychiatric Times, including positive clinical trial news for an ADHD treatment and an exclusive interview on the joint statement defending psychotropic medication safety.
In this CME article, learn more about the common neuropsychiatric sequelae of post-acute sequelae of COVID-19, the underlying neurobiological mechanisms, and evidence-based treatments and interventions.
The LGBTQIA+ community has faced marginalization and stereotyping in media, including video games. Let’s examine the intersection of identity, mental health, and video gaming.
A social psychiatrist who stays on the ethical way.
The prevalence of tobacco use in schizophrenia is over 60%—3 times that of the general population. However, the reason for the high prevalence of tobacco use in schizophrenia remains largely unknown.
Motherhood: what is truth vs idealized narrative?
Is the real March madness gambling?
"All redeeming Nature knows, You cannot stop the spring."
How do your fellow clinicians feel about ethical quandaries in psychiatry? Find out here.
Learn more about key findings on sex differences in cognition, exploring the possible causes and implications for clinical practice.
A psychiatrist reflects on the challenges we weather and the enduring search for hope and unity.
Disruptions to cognitive control, as well as to emotional processes, are implicated in a wide range of psychiatric disorders.
The FOCUS phase 3 trial of solriamfetol for the treatment of ADHD demonstrated statistically significant improvements in ADHD symptoms and disease severity.
We want to hear from you: what else can psychiatry do to address federal doubt?
Is psychiatry up to the challenge of protecting social well-being?
Cognitive symptoms affect between 85% and 94% of patients with major depressive disorder. Despite this prevalence, cognitive dysfunction often remains undertreated and inadequately addressed in routine clinical practice.
Given that individual differences exist regarding the effects of brain injury and gaps persist in the treatment continuum, challenges arise in treating individuals with acquired brain injury. Addressing these challenges can improve patient outcomes.
Remembering a psychiatrist and an activist…
Joint statements from leading psychiatric organizations voice concern about impact on patient care from executive orders and budget cuts.
Review various aspects of cognition in our latest Special Report.
Legislative and legal realities at the state and federal levels are difficult to navigate even for seasoned practitioners, and are beyond the knowledge of most families.
Check out new data from the long-term, open-label KINECT 4 study on Ingrezza capsules for the treatment of tardive dyskinesia.
Learn more about a condition that is often underestimated and mistaken for typical premenstrual symptoms or mood swings: premenstrual dysphoric disorder.
Residents and early career psychiatrists are concerned about the state of psychiatry.
Ketamine or ECT? A new study reveals which works best for severe depression—depending on the patient and setting.
Alzamend announced a late 2025 initiation for the phase 2 clinical study of AL001, a novel lithium-delivery system for the treatment of patients with major depressive disorder.
The REACH Institute announced new pathway to PMHS certification.
Through cinematherapy, Ted Perkins created a program centered on addiction in film that is now used in recovery centers and clinics across the US and Canada.